|  |
| --- |
| ICMJE DISCLOSURE FORM |
| **Date:** | 10/29/2022 |
| **Your Name:** | Nafisa Wara |
| **Manuscript Title:** | Preferences and Acceptability for Long-Acting PrEP Agents Among Pregnant and Postpartum Women with Experience Using Daily Oral PrEP in South Africa and Kenya |
| **Manuscript Number (if known):** | Click or tap here to enter text. |
| In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. |

|  | **Name all entities with whom you have this relationship or indicate none (add rows as needed)** | **Specifications/Comments (e.g., if payments were made to you or to your institution)** |
| --- | --- | --- |
| **Time frame: Since the initial planning of the work** |
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** |

|  |
| --- |
|[ ]  **None** |

|  |  |
| --- | --- |
| National Institute of Mental Health | R01MH116771 (Dvora Joseph Davey, Landon Myer) |
| The Eunice Kennedy Shriver National Institute of Child Health and Human Development | 1R01HD106821 (Dvora Joseph Davey)R01HD100201 (Jillian Pintye) |
| Fogarty International Center | K01TW011187 (Dvora Joseph Davey) |
| National Institute of Nursing Research | R01NR019220 (Jillian PIntye, John Kinuthia) |
| National Institutes of Allergy and Infectious Diseases | R01AI125498 (Grace John-Stewart) |

 |
| **Time frame: past 36 months** |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). |

|  |
| --- |
|[x]  **None** |

|  |  |
| --- | --- |
|  |  |
|  |  |
|  |  |

 |
| **3** | Royalties or licenses |

|  |
| --- |
|[x]  **None** |

|  |  |
| --- | --- |
|  |  |
|  |  |
|  |  |

 |
| **4** | Consulting fees |

|  |
| --- |
|[x]  **None** |

|  |  |
| --- | --- |
|  |  |
|  |  |
|  |  |
|  |  |

 |
| **5** | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events |

|  |
| --- |
|[x]  **None** |

|  |  |
| --- | --- |
|  |  |
|  |  |
|  |  |

 |
| **6** | Payment for expert testimony |

|  |
| --- |
|[x]  **None** |

|  |  |
| --- | --- |
|  |  |
|  |  |
|  |  |

 |
| **7** | Support for attending meetings and/or travel |

|  |
| --- |
|[ ]  **None** |

|  |  |
| --- | --- |
| University of California, Los Angeles David Geffen School of Medicine | Conference travel |
|  |  |
|  |  |

 |
| **8** | Patents planned, issued or pending |

|  |
| --- |
|[x]  **None** |

|  |  |
| --- | --- |
|  |  |
|  |  |
|  |  |

 |
| **9** | Participation on a Data Safety Monitoring Board or Advisory Board |

|  |
| --- |
|[x]  **None** |

|  |  |
| --- | --- |
|  |  |
|  |  |
|  |  |

 |
| **10** | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid |

|  |
| --- |
|[ ]  **None** |

|  |  |
| --- | --- |
| University of California David Geffen School of Medicine Global Health Interest Group | Committee leader, unpaid |
| University of California David Geffen School of Medicine Medicine-Pediatrics Interest Group | Committee leader, unpaid |
|  |  |

 |
| **11** | Stock or stock options |

|  |
| --- |
|[x]  **None** |

|  |  |
| --- | --- |
|  |  |
|  |  |
|  |  |

 |
| **12** | Receipt of equipment, materials, drugs, medical writing, gifts or other services |

|  |
| --- |
|[ ]  **None** |

|  |  |
| --- | --- |
| Gilead Sciences (Foster City, CA, USA) | The PrEP-PP study received the study drug (Truvada®) from Gilead Sciences. |
|  |  |
|  |  |

 |
| **13** | Other financial or non-financial interests |

|  |
| --- |
|[x]  **None** |

|  |  |
| --- | --- |
|  |  |
|  |  |
|  |  |

 |
|  |  |  |
| **Please place an “X” next to the following statement to indicate your agreement:** |
|[x]  I certify that I have answered every question and have not altered the wording of any of the questions on this form. |